Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02637557 · ClinicalTrials.gov registry record · Phase 2

A Trial of IW-3718 for 8 Weeks in Patients With Symptomatic Gastroesophageal Reflux Disease (GERD)

A Phase 2 study of Gastroesophageal Reflux Disease, sponsored by Ironwood Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
282
Enrollment target
20
Study locations

NCT02637557 is a Phase 2 study of Gastroesophageal Reflux Disease that has completed, run by Ironwood Pharmaceuticals. The registered enrollment target is 282 participants, below the 336-participant average among 24 other Gastroesophageal Reflux Disease trials with a reported enrollment target (16% lower). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02637557, a Phase 2 study of Gastroesophageal Reflux Disease, has completed, sponsored by Ironwood Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
282 participants
Enrollment target
20
Study locations

Study Summary

The objectives of this study are to evaluate the safety, efficacy, and dose-response relationship of IW-3718 administered orally to participants who have GERD and continue to experience GERD symptoms while receiving once-daily (QD), standard-dose proton pump inhibitors (PPIs).

Conditions Studied

Gastroesophageal Reflux Disease

Interventions

  • DRUG Matching Placebo
  • DRUG IW-3718
  • DRUG PPI

Study Locations (20)

California

  • IW-3718 Investigator - Anaheim
  • IW-3718 Investigator - Carmichael
  • IW-3718 Investigator - Chula Vista
  • IW-3718 Investigator - La Mirada
  • IW-3718 Investigator - Mission Hills
  • IW-3718 Investigator - Newport Beach
  • IW-3718 Investigator - Oakland
  • IW-3718 Investigator - Sacramento
  • IW-3718 Investigator - San Diego

Arizona

  • IW-3718 Investigator - Phoenix
  • IW-3718 Investigator - Tucson
  • IW-3718 Investigator - Tucson
  • IW-3718 Investigator - Tucson

Florida

  • IW-3718 Investigator - DeLand
  • IW-3718 Investigator - Hollywood
  • IW-3718 Investigator - Inverness

Connecticut

  • IW-3718 Investigator - Bristol
  • IW-3718 Investigator - Waterbury

Alabama

  • IW-3718 Investigator - Dothan

Arkansas

  • IW-3718 Investigator - North Little Rock

Trial Details

FieldValue
Enrollment Target 282 participants
Start Date 2016-03-01
Est. Completion 2017-04-26
Phase Phase 2

Sponsor

Ironwood Pharmaceuticals

23 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02637557

The ClinicalTrials.gov registry entry for NCT02637557 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 282 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 336-participant average among 24 other Gastroesophageal Reflux Disease trials with a reported enrollment target (16% lower). The listed sponsor is Ironwood Pharmaceuticals, which has 23 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Gastroesophageal Reflux Disease appearing as the primary indexed condition, and to 3 interventions - of which Matching Placebo is the first listed.

NCT02637557 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Arizona, Florida.

Frequently Asked Questions

What is clinical trial NCT02637557 about?

NCT02637557 is a clinical study titled "A Trial of IW-3718 for 8 Weeks in Patients With Symptomatic Gastroesophageal Reflux Disease (GERD)". The objectives of this study are to evaluate the safety, efficacy, and dose-response relationship of IW-3718 administered orally to participants who have GERD and continue to experience GERD symptoms while receiving once-daily (QD), standard-dose proton pump inhibitors (PPIs).

What is the current status of trial NCT02637557?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 282 participants. The study started on 2016-03-01. Estimated completion is 2017-04-26.

What conditions does trial NCT02637557 study?

This clinical trial studies the following conditions: Gastroesophageal Reflux Disease.

What interventions are being tested in trial NCT02637557?

The interventions under investigation include: Matching Placebo (DRUG), IW-3718 (DRUG), PPI (DRUG).

Who is sponsoring clinical trial NCT02637557?

This trial is sponsored by Ironwood Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02637557 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Gastroesophageal Reflux Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Gastroesophageal Reflux Disease

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.